Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding ...

Wells Fargo analyst Yanan Zhu assigned a Hold rating to Sangamo Biosciences (SGMO – Research Report) yesterday and set a price target of ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of $10.00. Patrick Trucchio’s rating is based on Sangamo ...

Sangamo (SGMO) delivered earnings and revenue surprises of 233.33% and 86.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

RBC Capital Mkts has recently reduced Sangamo Therapeutics Inc (SGMO) stock to Sector Perform rating, as announced on November 3, 2023, according to Finviz. Earlier, on April 28, 2023, BofA Securities ...

(SGMO) on Tuesday reported third-quarter earnings of $10.7 million. On a per-share basis, the Richmond, California-based company said it had profit of 4 cents. The results exceeded Wall Street ...

Shares of SGMO stock opened at $2.87 on Monday. The firm has a fifty day simple moving average of $1.16 and a 200-day simple moving average of $0.80. The company has a market capitalization of $ ...

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) reached a new 52-week high on Wednesday after HC Wainwright raised their price target on the stock from $5.00 to $10.00. HC ...

Sangamo Therapeutics SGMO is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial results. "This is ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...